Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF

Journal of Clinical Virology

Volumn 32, Issue 3, 2005, Pages 241-244

  Delaugerre, Constance ^a   Roudiere, Laurent ^a   Peytavin, Gilles ^b   Rouzioux, Christine ^a   Viard, Jean Paul ^a   Chaix, Marie Laure ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

HIV 1; K65R; K70E; Resistance pattern; Tenofovir; Virologic failure

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; LOPINAVIR PLUS RITONAVIR; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DISEASE CONTROL; DRUG HYPERSENSITIVITY; DRUG POTENCY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIDE EFFECT; VIROLOGY; VIRUS LOAD;

EID: 13844277070     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.05.020     Document Type: Article

References (27)

1. J.M. Cherrington, A.S. Mulato, M.D. Fuller, and M.S. Chen Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro Antimicrob Agents Chemother 40 1996 2212 2216
2. A. De Antoni, A. Foli, J. Lisziewicz, and F. Lori Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy J Infect Dis 176 1997 899 903
3. C. Farthing, H. Khanlou, and V. Yeh Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients Proceedings of the 2nd International AIDS Society Conference on Pathogenesis and Treatment Paris, France 2003
4. J. Gallant, A. Rodriguez, W. Weinberg, B. Young, D. Berger, M. Lim, Q. Liao, L. Ross, J. Johnson, and M. Shaefer Early non-response to tenofovir+abacavir and lamivudine in a randomized trial compared to efavirenz+abacavir and lamivudine: ES30009 unplanned interim analysis Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA 2003
5. J.G. Garcia-Lerma, H. MacInnes, D. Bennett, P. Reid, S. Nidtha, H. Weinstock, J.E. Kaplan, and W. Heneine A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation J Virol 77 2003 5685 5693
6. Z. Gu, Q. Gao, H. Fang, H. Salomon, M.A. Parniak, E. Goldberg, J. Cameron, and M.A. Wainberg Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy- 3′-thiacytidine Antimicrob Agents Chemother 38 1994 275 281
7. M. Hoogewerf, R.M. Regez, W.E. Schouten, H.M. Weigel, P.H. Frissen, and K. Brinkman Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression Lancet 362 2003 1979 1980
8. J. Jemsek, P. Hutcherson, and E. Harper Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patient receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections San Francisco, USA 2004
9. R. Landman, G. Peytavin, D. Descamps, F. Brun-Vezinet, H. Benech, A. Benalisherif, A. Trylesinski, C. Katlama, P. Girard, F. Raffi, P. Yeni, M. Bentata, B. Jarrousse, C. Michelet, and P. Flandre Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the TONUS study Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections San Francisco, USA 2004
10. N.A. Margot, E. Isaacson, I. McGowan, A. Cheng, and M.D. Miller Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses J Acquir Immune Defic Syndr 33 2003 15 21
11. N.A. Margot, E. Isaacson, I. McGowan, A.K. Cheng, R.T. Schooley, and M.D. Miller Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF AIDS 16 2002 1227 1235
12. M. Miller, N. Margot, D.J. McColl, D.F. Coakley, and A. Cheng Characteristic of virologic failure through 96 weeks among treatment naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz Proceedings of the 2nd International AIDS Society Conference on Pathogenesis and Treatment Paris, France 2003
13. M.D. Miller, K.E. Anton, A.S. Mulato, P.D. Lamy, and J.M. Cherrington Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro J Infect Dis 179 1999 92 100
14. M.D. Miller, P.D. Lamy, M.D. Fuller, A.S. Mulato, N.A. Margot, T. Cihlar, and J.M. Cherrington Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity Mol Pharmacol 54 1998 291 297
15. M.D. Miller, N. Margot, B. Lu, L. Zhong, S.S. Chen, A. Cheng, and M. Wulfsohn Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients J Infect Dis 189 2004 837 846 Epub 2004 Feb 10
16. M. Mouroux, D. Descamps, J. Izopet, A. Yvon, C. Delaugerre, S. Matheron, A. Coutellier, M.A. Valantin, M. Bonmarchand, H. Agut, P. Massip, D. Costagliola, C. Katlama, F. Brun-Vezinet, and V. Calvez Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy Antivir Ther 6 2001 179 183
17. A.S. Mulato, P.D. Lamy, M.D. Miller, W.X. Li, K.E. Anton, N.S. Hellmann, and J.M. Cherrington Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy Antimicrob Agents Chemother 42 1998 1620 1628
18. U. Parikh, D. Koontz, N. Sluis-Cremer, J. Hammond, L. Bacheler, R.F. Schinazi, and J. Mellors K65R: A multinucleoside resistance mutation of increasing prevalence exhibits bi-directionnal phenotypic antagonism with TAM Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections San Francisco, USA 2004
19. V. Picard, E. Angelini, A. Maillard, E. Race, F. Clavel, G. Chene, F. Ferchal, and J.M. Molina Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine J Infect Dis 184 2001 781 784
20. B.T. Roge, T.L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren, and J. Gerstoft K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine Antivir Ther 8 2003 173 182
21. T. Shirasaka, M.F. Kavlick, T. Ueno, W.Y. Gao, E. Kojima, M.L. Alcaide, S. Chokekijchai, B.M. Roy, E. Arnold, and R. Yarchoan Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides Proc Natl Acad Sci USA 92 1995 2398 2402
22. K. Squires, A.L. Pozniak, G. Pierone Jr., C.R. Steinhart, D. Berger, N.C. Bellos, S.L. Becker, M. Wulfsohn, M.D. Miller, J.J. Toole, D.F. Coakley, and A. Cheng Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial Ann Intern Med 139 2003 313 320
23. R.V. Srinivas, and A. Fridland Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains Antimicrob Agents Chemother 42 1998 1484 1487
24. M. Tisdale, T. Alnadaf, and D. Cousens Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89 Antimicrob Agents Chemother 41 1997 1094 1098
25. M.A. Wainberg, M.D. Miller, Y. Quan, H. Salomon, A.S. Mulato, P.D. Lamy, N.A. Margot, K.E. Anton, and J.M. Cherrington In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA Antivir Ther 4 1999 87 94
26. A. Winston, S. Mandalia, D. Pillay, B. Gazzard, and A. Pozniak The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients AIDS 16 2002 2087 2089
27. A. Winston, A. Pozniak, S. Mandalia, B. Gazzard, D. Pillay, and M. Nelson Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase AIDS 18 2004 949 951